127 related articles for article (PubMed ID: 9847957)
1. Hydroxyurea-induced fever and hepatitis.
Westerman DA; Schwarer A; Grigg AP
Aust N Z J Med; 1998 Oct; 28(5):657-9. PubMed ID: 9847957
[No Abstract] [Full Text] [Related]
2. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
Dingli D; Tefferi A
Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
[TBL] [Abstract][Full Text] [Related]
3. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
4. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
Brodsky I
Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
[No Abstract] [Full Text] [Related]
5. Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
Christoforidou A; Pantelidou D; Anastasiadis A; Goutzouvelidis A; Margaritis D; Kotsianidis I; Spanoudakis E; Kaloutsi V; Bourikas G; Tsatalas C
Acta Haematol; 2008; 120(4):195-8. PubMed ID: 19129692
[No Abstract] [Full Text] [Related]
6. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
[TBL] [Abstract][Full Text] [Related]
7. Unwanted side effect of hydroxyurea.
Najean Y
Ann Hematol; 1996 Feb; 72(2):101. PubMed ID: 8597606
[No Abstract] [Full Text] [Related]
8. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
Ricksten A; Palmqvist L; Johansson P; Andreasson B
Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
[No Abstract] [Full Text] [Related]
9. Is hydroxyurea leukemogenic in essential thrombocythemia?
Tefferi A
Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
[No Abstract] [Full Text] [Related]
10. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea as a cause of drug fever.
Braester A; Quitt M
Acta Haematol; 2000; 104(1):50-1. PubMed ID: 11111124
[TBL] [Abstract][Full Text] [Related]
12. [Fever induced by hydroxycarbamide].
Lizarralde Palacios E; Gutiérrez Macías A; Rámiz Martínez M; Escalante Boleas M
Med Clin (Barc); 2015 Dec; 145(11):505-6. PubMed ID: 25817448
[No Abstract] [Full Text] [Related]
13. [Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases].
Gallant C; Vial T; Allochon Y; Monier JM; Blanc M; Evreux JC
Ann Med Interne (Paris); 1998 Mar; 149(2):59-61. PubMed ID: 11490525
[TBL] [Abstract][Full Text] [Related]
14. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
15. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
16. Recurrent pyrexia, cough and dyspnoea with hydroxyurea.
Grace RF; Shenfield GM; Grant J; Ravich R
Aust N Z J Med; 1998 Jun; 28(3):347. PubMed ID: 9673751
[No Abstract] [Full Text] [Related]
17. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
Johansson P; Andréasson B
Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea induced acute elevations in liver function tests.
Hallam MJ; Kolesar JM
J Oncol Pharm Pract; 2008 Mar; 14(1):61-3. PubMed ID: 18337443
[TBL] [Abstract][Full Text] [Related]
20. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
Zhang ZR; Duan YC
Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
